We are studying the role of GDPD6 in breast cancer, as well as its potential as a therapeutic target. GDPD6 silencing experiments showed decreased invasion and migration in breast cancer cells. There is currently no small molecule inhibitor for GDPD6. We have identified dipyridamole as potential GDPD6 inhibitor, which can be used both in the lab and potentially in the clinic. We are using a combination of 1H MRS and computational studies to determine how dipyridamole inhibits GDPD6 to evaluate its potential as an inhibitor and identify other potential small molecule inhibitors of GDPD6.